Is plateau normal?
Yes, it's a feature of weight loss biology.
Can I push past plateau?
Sometimes, through dose escalation, product switch, tightened lifestyle, or resistance training.
When does plateau typically happen?
Week 28-40 on semaglutide at therapeutic doses.
Should I increase my dose?
Yes if not at maximum; if at 2 mg, consider product change.
How long before changing strategy?
8-12 weeks of true plateau at maximum tolerated dose.
Will I gain back weight?
Continued therapy typically maintains loss.
Is it okay to stop at the weight I've lost?
Often the right answer; maintenance is legitimate.
Could it be the medication wearing off?
Tolerance is uncommon; plateau is biological adaptation.
Should I switch products?
Reasonable consideration at max Ozempic; Wegovy 2.4 mg or tirzepatide common options.
- Why Am I Not Losing Weight on Mounjaro? Plateau Patterns and Real Causes
- Does Ozempic Make You Cold? Thermoregulation After Rapid Weight Loss
- Why Am I Not Losing Weight on Zepbound? Plateau Realities and Course Correction
- How Often Should I Poop on Ozempic? Bowel Patterns Explained
- Ozempic and Loose Skin: A Weight-Loss Phenomenon, Not an Ozempic Phenomenon
- Why Am I Not Losing Weight on Ozempic? The Six Causes Worth Investigating
Sources
- Ozempic FDA prescribing information
- Wegovy FDA prescribing information
- Tasali E et al., JAMA Internal Medicine March 2022
- National Sleep Foundation duration guidance
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022.
Platform Disclaimer. FormBlends connects patients with licensed clinicians for GLP-1 therapy. This article is educational. Individual situations require clinical assessment by your prescriber.
Compounded Medication Notice. Compounded semaglutide is prepared by 503A pharmacy partners for individual patients with documented clinical justification. Not FDA-approved. STEP trial data applies to brand Wegovy and Ozempic.
Results Disclaimer. Individual outcomes vary. STEP 1 mean of 14.9% includes high responders and modest responders. Plateau is expected; maintenance is a legitimate outcome.
Trademark Notice. Ozempic, Wegovy are trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are trademarks of Eli Lilly. FormBlends is independent.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →